Funder: National Institutes of Health (NIH)
Due Dates: June 23, 2025 (New/Renewal/Resubmission) | October 20, 2026 (New/Renewal/Resubmission)
Funding Amounts: Recommended up to $350,000 direct costs per year | Project period up to 3 years (max 5 years)
Summary: Supports investigator-initiated mid-phase clinical trials of natural products to optimize dosing/formulation or identify responder phenotypes, excluding cancer treatment trials.
Key Information: Requires sufficient preliminary data on bioavailability and target engagement; FDA IND/IDE compliance required if applicable.